TY - JOUR
T1 - Primer consenso Mexicano de cancer de endometrio.
AU - Ruvalcaba-Limón, Eva
AU - Cantú-de-León, David
AU - León-Rodríguez, Eucario
AU - Cortés-Esteban, Patricia
AU - Serrano-Olvera, Alberto
AU - Morales-Vásquez, Flavia
AU - Sosa-Sánchez, Ricardo
AU - Poveda-Velasco, Andrés
AU - Crismatt-Zapata, Alejandro
AU - Santillán-Gómez, Antonio
AU - Aguilar-Jiménez, Carmen
AU - Alanís-López, Patricia
AU - Alfaro-Ramírez, Paulino
AU - Alvarez-Avitia, Miguel Angel
AU - Aranda-Flores, Carlos Eduardo
AU - Arias-Ceballos, José Héctor Reynaldo
AU - Arrieta-Rodríguez, Oscar
AU - Barragán-Curiel, Eduardo
AU - Botello-Hernández, Daniel
AU - Brom-Valladares, Rocío
AU - Cabrera-Galeana, Paula Anel
AU - Cantón-Romero, Juan Carlos
AU - Capdeville-García, Daniel
AU - Cárdenas-Sánchez, Jesús
AU - Castorena-Roji, Gerardo
AU - Cepeda-López, Friedman Rafael
AU - Cervantes-Sánchez, Guadalupe
AU - Cetina-Pérez, Lucely de Carmen
AU - Coronel-Martínez, Jaime Alberto
AU - Cortés-Cárdenas, Seir Alfonso
AU - Cruz-López, Juan Carlos
AU - de la Garza-Salazar, Jaime G.
AU - Díaz-Romero, Consuelo
AU - Dueñas-González, Alfonso
AU - Valle-Solís, Aura Erazo
AU - Escudero-de los Ríos, Pedro
AU - Flores-Alvarez, Efrén
AU - García-Matus, Rolando
AU - Gerson-Cwilich, Raquel
AU - González-Enciso, Aarón
AU - González-de-León, César
AU - Guevara-Torres, Alfonso Genaro
AU - Herbert-Núñez, Guillermo Sidney
AU - Hernández-Hernández, Carlos
AU - Hernández-Hernández, Dulce María
AU - Isla-Ortiz, David
AU - Jesús-Sandoval, Ramiro
AU - Jiménez-Cervantes, Carlos
AU - Kuri-Exsome, Roberto
AU - López-Obispo, José Luis
AU - Maffuz-Aziz, Antonio
AU - Martínez-Barrera, Luis Manuel
AU - Medina-Castro, Juan Manuel
AU - Montalvo-Esquivel, Gonzalo
AU - Mora-Aguilar, Víctor Hugo
AU - Morales-Palomares, Miguel Angel
AU - Morán-Mendoza, Andrés
AU - Morgan-Villela, Gilberto
AU - Mota-García, Aída
AU - Muñoz-González, David Eduardo
AU - Murillo-Cruz, Dino Alberto
AU - Novoa-Vargas, Arturo
AU - Ochoa-Carrillo, Francisco J.
AU - Oñate-Ocaña, Luis Fernando
AU - Ortega-Rojo, Andrea
AU - Palacios-Martínez, Alma Georgina
AU - Palomeque-López, Antonio
AU - Pérez-Montiel, María Delia
AU - Quijano-Castro, Félix
AU - Rivera-Rivera, Samuel
AU - Rivera-Rubí, Lesbia María
AU - Robles-Flores, Juan Ubaldo
AU - Rodríguez-Trejo, Amelia
AU - Salas-Gonzáles, Efraín
AU - Silva, Juan Alejandro
AU - Solorza-Luna, Gilberto
AU - Souto-del-Bosque, Rosalía
AU - Tirado-Gómez, Laura Leticia
AU - Torrescano-González, Salvador
AU - Torres-Lobatón, Alfonso
AU - Trejo-Durán, Elizabeth
AU - Villavicencio-Valencia, Verónica
AU - Gallardo-Rincón, Dolores
AU - Grupo de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico, de Investigacion en Cancer de Ovario y Tumores Ginecologicos de Mexico
PY - 2010/11
Y1 - 2010/11
N2 - Endometrial cancer (EC) is the second most common gynecologic malignancy worldwide in the peri and postmenopausal period. Most often for the endometrioid variety. In early clinical stages long-term survival is greater than 80%, while in advanced stages it is less than 50%. In our country there is not a standard management between institutions. GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of four days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II). Endometrial thickness in postmenopausal patients is best evaluated by transvaginal US, a thickness greater than or equal to 5 mm must be evaluated. Women taking tamoxifen should be monitored using this method. Abnormal bleeding in the usual main symptom, all post menopausal women with vaginal bleeding should be evaluated. Diagnosis is made by histerescopy-guided biopsy. Magnetic resonance is the best image method as preoperative evaluation. Frozen section evaluates histologic grade, myometrial invasion, cervical and adnexal involvement. Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus. Omentectomy should be done in histologies other than endometriod. Surgery should be always performed by a Gynecologic Oncologist or Surgical Oncologist, laparoscopy is an alternative, especially in patients with hypertension and diabetes for being less morbid. Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy. Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy. Follow-up of patients is basically clinical in a regular basis. Screening programme is only for high risk patients. Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence. This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.
AB - Endometrial cancer (EC) is the second most common gynecologic malignancy worldwide in the peri and postmenopausal period. Most often for the endometrioid variety. In early clinical stages long-term survival is greater than 80%, while in advanced stages it is less than 50%. In our country there is not a standard management between institutions. GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of four days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II). Endometrial thickness in postmenopausal patients is best evaluated by transvaginal US, a thickness greater than or equal to 5 mm must be evaluated. Women taking tamoxifen should be monitored using this method. Abnormal bleeding in the usual main symptom, all post menopausal women with vaginal bleeding should be evaluated. Diagnosis is made by histerescopy-guided biopsy. Magnetic resonance is the best image method as preoperative evaluation. Frozen section evaluates histologic grade, myometrial invasion, cervical and adnexal involvement. Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus. Omentectomy should be done in histologies other than endometriod. Surgery should be always performed by a Gynecologic Oncologist or Surgical Oncologist, laparoscopy is an alternative, especially in patients with hypertension and diabetes for being less morbid. Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy. Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy. Follow-up of patients is basically clinical in a regular basis. Screening programme is only for high risk patients. Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence. This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.
UR - http://www.scopus.com/inward/record.url?scp=79955714746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955714746&partnerID=8YFLogxK
M3 - Article
C2 - 21416918
AN - SCOPUS:79955714746
VL - 62
SP - 583, 585-605
JO - Revista de Investigacion Clinica
JF - Revista de Investigacion Clinica
SN - 0034-8376
IS - 6
ER -